| Objection: Multiple myeloma(MM) is a common tumor in the hematological system. But until now,MM has not been cured by either routine chemotherapy or large doses chemotherapy.To overcome the resistance to chemotherapy and amend curative effect,people have been developing new therapeutic strategies,including aiming at classical targets as DNA or framework of cells and modulating directionally molecule approach of proliferation and survival of cells. Recent years thalidomide (Thd) has been applied for MM and succeeds in treating MM. Its mechanism is still unknown. Most scientists can't tolerate thalidomide, because its large doses and toxic and side reactions. New studies have implied Notch signal as a treated target in hematological and solid tumors. We will discuss whether thalidomide has an impact on myeloma cells by Notch signal, and provide a laboratory foundation for mechanism of thalidomide and gene therapy and new drugs.Methods: 1) human myeloma U266 cells and HFCL cells were cultured together,and protracted their growth curve.there were four groups: A: U266 cells group. B: U266 cells+S-Thd group. C: U266 cells+ HFCL. D: U266 cells+ HFCL+S-Thd group. When HFCL cells inosulated to 70-80%, irradiation at dose of 25 Gy was given. Each pore in B and D groups was given 2.5ul S-Thd original liquid respectively, namely final concentration of S-Thd was 100ug/ml. Each pore in A and C groups was given 2.5ul DMSO as control. After 24, 48, 72hours of culturing,U266 cells of each group were stained by typan blue, then protracted their growth curve. 2) S-Thd induced U266 cells apoptositic: After 72hours of culturing, U266 cells of each group were detected whether apoptosis occurred by Giemsa staining. TUNEL and DNA ladder methods. 3) S-Thd can change the expression of Notch2. Overexpression of Hes-1 indicates activation of Notch indirectly. By competitive RT-PCR method, we detected the changes of expression of Hes-1 of U266 cells in four groups after 72 hours. |
PDF Full Text Request